+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rosacea Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5178012
  • Report
  • August 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Aclaris Therapeutics
  • Amorepacific Corporation
  • Foamix Pharmaceuticals
  • Hovione FarmaCiencia SA
  • Leo Pharma Inc.
  • Nestlé
  • MORE
  • Rosacea is a common skin disease, which causes redness and visible blood vessels on the face. It commonly affects middle-aged women who have fair skin. Although there is no cure for rosacea, treatments can control and reduce the signs and symptoms associated with the disease.
  • As per the National Rosacea Society, United States, the prevalence of rosacea during 2018 was highest when self-reported, with a rate of 9.71 %( 737,960,000), while the rate of dermatologist-diagnosed rosacea was 5.53 % (420,280,000). It has been observed in several studies that this is more common in fair-skinned individuals.
  • With rising prevalence, the awareness among the physicians and societies has also increased, which further drives the demand of this market. However, the presence of generic drugs to curb the related symptoms hinders the growth of the rosacea market.
Key Market Trends

Antibiotics is Estimated to Witness Healthy Growth Over the Forecast Period

For over 60 years, antibiotics have been prescribed as a treatment for the symptoms of rosacea. It can reduce the number of acne pimples and bacterial inflammation or redness around the acne pimples. Antibiotics are available in two forms, including oral antibiotics and topical antibiotics. Oral antibiotics, such as tetracycline, doxycycline, and minocycline, have been proven to control rosacea's bacterial component and also has inflammatory benefits. It is most commonly preferred by physicians and doctors for early relief from the disease, but are usually for a long period, which drives the sales of this segment over other sub segments. So, the high usage of antibiotics for the treatment of rosacea is the main factor for the growth of the market. However, there are certain side effects associated with the usage of antibiotics, including bloating, loss of appetite, abdominal pain, and many others, which are restraining their adoption as a treatment.

North America is Expected to Maintain the Largest Share in the Rosacea Market

North America has multiple factors, which support the growth of this market, better than other geographic regions. Some factors include high healthcare expenditure by the government each year on pharmaceuticals and medical devices and awareness in the society (several societies organizing campaigns across the US and Canada). As per the estimates of the National Rosacea Society (NRS), about 16 million Americans suffer from rosacea and maybe millions more in temporary remission. The companies also prefer to release their products first in the United States, due to favorable regulatory requirements, which drives the demand for this market

Competitive Landscape

The rosacea market has observed growing competition among leading players, majorly across the developed markets. Some of the major market players include Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aclaris Therapeutics
  • Amorepacific Corporation
  • Foamix Pharmaceuticals
  • Hovione FarmaCiencia SA
  • Leo Pharma Inc.
  • Nestlé
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Rosacea
4.2.2 Increasing Inclination toward Combination Products
4.3 Market Restraints
4.3.1 Increased Use of Generic Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Antibiotics
5.1.2 Alpha Agonists
5.1.3 Retinoid
5.1.4 Corticosteroids
5.1.5 Immunosuppressants
5.1.6 Other Drug Classes
5.2 By Mode of Administration
5.2.1 Topical
5.2.2 Oral
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aclaris Therapeutics
6.1.2 Amorepacific Corporation
6.1.3 Bausch Health Companies Inc.
6.1.4 Foamix Pharmaceuticals
6.1.5 Hovione FarmaCiencia SA
6.1.6 Leo Pharma Inc.
6.1.7 Nestlé

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Aclaris Therapeutics
  • Amorepacific Corporation
  • Bausch Health Companies Inc.
  • Foamix Pharmaceuticals
  • Hovione FarmaCiencia SA
  • Leo Pharma Inc.
  • Nestlé
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll